What type of study is this?

This is a Meta-Analysis study (also classified as: Systematic Review).

December 8, 2025BloodOpen Access

Efficacy and safety of venetoclax in high-risk Relapsed/Refractory AL amyloidosis: A systematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

Authors

Systematic review highlights venetoclax improves overall response rates in high-risk AL amyloidosis, indicating strong survival outcomes.

Evaluate efficacy and safety of venetoclax in high-risk relapsed/refractory AL amyloidosis patients.
Conducted a systematic review and meta-analysis according to PRISMA 2020 guidelines.
Searched Pubmed, Embase, and Cochrane for original studies on venetoclax in AL amyloidosis.
Included eleven studies reporting baseline characteristics and clinical outcomes.
Pooled overall response rate was 83% with a complete response rate of 45%.
14% all-cause mortality noted, with disease-related mortality at 9%.
Pooled overall survival was 79% at 1 year and 74% at 2 years.

Khan et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark